ImmunohematologyPub Date : 2023-04-01DOI: 10.21307/immunohematology-2023-007
S Sawadogo, K Nebie, S K A Ouedraogo, C Traore, J Koulidiati, M Nikiema-Minoungou, N G Koala, E Kafando, V Deneys
{"title":"Extended red blood cell antigens and phenotypes in Burkina Faso: potential issues to design local population-sourced red blood cell reagent panels.","authors":"S Sawadogo, K Nebie, S K A Ouedraogo, C Traore, J Koulidiati, M Nikiema-Minoungou, N G Koala, E Kafando, V Deneys","doi":"10.21307/immunohematology-2023-007","DOIUrl":"https://doi.org/10.21307/immunohematology-2023-007","url":null,"abstract":"<p><p>To date, 43 blood group systems with 349 red blood cell (RBC) antigens have been recognized. The study of their distribution is useful for blood services to improve their supply strategies for providing blood of rare phenotypes, but also to design indigenous RBC panels for alloantibody screening and identification. In Burkina Faso, the distribution of extended blood group antigens is not known. This study aimed to investigate the extended profiles of blood group antigens and phenotypes of this population and to raise limitations and potential strategies for the design of local RBC panels. We conducted a cross-sectional study that included group O blood donors. Extended phenotyping for antigens in the Rh, Kell, Kidd, Duffy, Lewis, MNS, and P1PK systems was performed using the conventional serologic tube technique. The prevalence of each antigen and phenotype combination was determined. A total of 763 blood donors were included. The majority were positive for D, c, e, and k and negative for Fy<sup>a</sup> and Fy<sup>b</sup>. The prevalence of K, Fy<sup>a</sup>, Fy<sup>b</sup>, and C<sup>w</sup> was less than 5 percent. The most frequent Rh phenotype was Dce, and the most common probable haplotype was R<sub>0</sub>R<sub>0</sub> (69.5%). For the other blood group systems, the K-k+ (99.4%), M+N+S+s- (43.4%), and Fy(a-b-) (98.8%) phenotypes were the most frequent. Antigenic polymorphism of blood group systems by ethnicity and geography argues for the design and evaluation of population-sourced RBC panels to meet specific antibody profiles. However, some of the specificities identified in our study, such as the rarity of double-dose antigen profiles for certain antigens and the cost of antigen phenotyping tests, are major challenges to overcome.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"39 1","pages":"35-42"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9263145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ImmunohematologyPub Date : 2023-04-01DOI: 10.21307/immunohematology-2023-003
D Sahoo, S Anuragaa, B Abhishekh
{"title":"Anti-C causing severe hemolytic disease of the fetus and newborn: a rare case report.","authors":"D Sahoo, S Anuragaa, B Abhishekh","doi":"10.21307/immunohematology-2023-003","DOIUrl":"https://doi.org/10.21307/immunohematology-2023-003","url":null,"abstract":"<p><p>Hemolytic disease of the fetus and newborn (HDFN) due to anti-D was severe and fatal before the development of RhD immune prophylaxis. Proper screening and universal administration of Rh immune globulin has decreased the incidence of HDFN to a great extent. Pregnancy, transfusion, and transplantation still increase the chances of other alloantibody formation and the potential for HDFN. Advanced methods for immunohematology investigation allow for the identification of alloantibodies causative for HDFN other than anti-D. Many antibodies have been reported to cause HDFN, but there is scant literature where isolated anti-C is responsible for HDFN. We present here a case of severe HDFN caused by anti-C leading to severe hydrops and death of the neonate despite three intrauterine transfusions and other measures.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"39 1","pages":"11-14"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9263148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ImmunohematologyPub Date : 2023-04-01DOI: 10.21307/immunohematology-2023-006
J W Jacobs, E Abels, T C Binns, C A Tormey, N Sostin
{"title":"Hemolytic disease of the fetus and newborn mediated by anti-Di<sup>a</sup> in a U.S. hospital.","authors":"J W Jacobs, E Abels, T C Binns, C A Tormey, N Sostin","doi":"10.21307/immunohematology-2023-006","DOIUrl":"https://doi.org/10.21307/immunohematology-2023-006","url":null,"abstract":"<p><p>Di<sup>a</sup> is one of the most clinically significant low-prevalence antigens in the Diego blood group system, since antibodies to Di<sup>a</sup> have, albeit rarely, been implicated in hemolytic transfusion reactions and hemolytic disease of the fetus and newborn (HDFN). Given the geographical association, most anti-Di<sup>a</sup> HDFN cases have been reported in Japan, China, and Poland. We describe a case of HDFN in a neonate born to a 36-year-old G4P2012 woman of self-identified Hispanic ethnicity and of South American descent with multiple negative antibody detection tests in a U.S. hospital. Upon delivery, a cord blood direct antiglobulin test was positive (3+ reactivity), and neonatal bilirubin levels were moderately elevated, but phototherapy and transfusion were not required. This case highlights a rare, unexpected cause of HDFN in the United States secondary to anti-Di<sup>a</sup>, given the near-universal absence of this antigen and antibody in most U.S. patient populations. The case also demonstrates the need for awareness of antibodies to antigens that are considered \"low-prevalence\" in most populations but that might be encountered more frequently in specific racial or ethnic groups and may require more extensive testing.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"39 1","pages":"32-34"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9263149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ImmunohematologyPub Date : 2022-12-01DOI: 10.21307/immunohematology-2022-060
Margaret A Keller, Cynthia Flickinger
{"title":"To contributors to the 2022 issues.","authors":"Margaret A Keller, Cynthia Flickinger","doi":"10.21307/immunohematology-2022-060","DOIUrl":"https://doi.org/10.21307/immunohematology-2022-060","url":null,"abstract":"","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"38 4","pages":"142"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ImmunohematologyPub Date : 2022-12-01DOI: 10.21307/immunohematology-2022-053
H Ohto, M Uchikawa, S Ito, I Wada, K E Nollet, Y Omae, K Ogasawara, K Tokunaga
{"title":"The KANNO blood group system.","authors":"H Ohto, M Uchikawa, S Ito, I Wada, K E Nollet, Y Omae, K Ogasawara, K Tokunaga","doi":"10.21307/immunohematology-2022-053","DOIUrl":"https://doi.org/10.21307/immunohematology-2022-053","url":null,"abstract":"Abstract The KANNO blood group system (International Society of Blood Transfusion [ISBT] 037) includes one high-prevalence antigen, KANNO1, across ethnic groups. Sporadic KANNO1− cases among East and South Asians are theoretically estimated by the DNA database library. Anti-KANNO1 has been found most often among Japanese women with current or prior pregnancy. Thus far, there are no reported cases of hemolytic transfusion reaction or hemolytic disease of the fetus and newborn due to anti-KANNO1.","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"38 4","pages":"119-122"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ImmunohematologyPub Date : 2022-12-01DOI: 10.21307/immunohematology-2022-054
C P Arnoni, T A P Vendrame, F S Silva, A J P Cortez, F R M Latini, L Castilho
{"title":"<i>RHCE</i> variant alleles and risk of alloimmunization in Brazilians.","authors":"C P Arnoni, T A P Vendrame, F S Silva, A J P Cortez, F R M Latini, L Castilho","doi":"10.21307/immunohematology-2022-054","DOIUrl":"https://doi.org/10.21307/immunohematology-2022-054","url":null,"abstract":"<p><p>Variant <i>RHCE</i> alleles are found mainly in Afro-descendant individuals, as well as in patients with sickle cell disease (SCD). The most common variants are related to the <i>RHCE*ce</i> allele, which can generate partial e and c antigens. Although <i>RHCE</i> variant alleles have been extensively studied, defining their clinical significance is a difficult task. We evaluated the risk of RhCE alloimmunization as a consequence of partial antigens in patients with a positive phenotype transfused with red blood cell (RBC) units with the corresponding antigen. A retrospective study was performed with Brazilian patients, evaluating the number of antigen-positive transfused RBC units (incompatible due to partial antigen) in 27 patients with SCD carrying <i>RHCE</i> variant alleles who did not develop antibodies as well as evaluating the variants present in 12 patients with partial phenotype and correlated antibody (one patient with SCD and 11 patients with other pathologies). Two patients showed variant alleles with molecular changes that had not yet been described. Variant <i>RHCE</i> alleles were identified in a previous study using molecular methods. <i>RHCE*ceVS.01</i> was the most frequent allele found among the patients without antibodies. Six patients with partial c antigen had a mean of 3.8 c+ RBC units transfused, and 10 patients with partial e antigen were exposed for a mean of 7.2 e+ RBC units. Among the variant alleles found in alloimmunized patients, the most frequent was <i>RHCE*ceAR,</i> which was found in five patients; the antibodies developed were anti-hr<sup>S</sup> and/or anti-c. Our results showed that <i>RHCE*ceVS.01</i> is indeed the most frequent variant allele in our cohort of patients with SCD, but the partial antigens that were identified have low risk of alloimmunization. <i>RHCE*ceAR</i> is the most impactful variant in the Brazilian population with high risk of alloimmunization and clinically significant anti-hr<sup>S</sup> formation.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"38 4","pages":"123-129"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10731419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ImmunohematologyPub Date : 2022-12-01DOI: 10.21307/immunohematology-2022-055
M D Ilsley, J R Storry, M L Olsson
{"title":"Yes, MAM: how the cancer-related EMP3 protein became a regulator of erythropoiesis and the key protein underlying a new blood group system.","authors":"M D Ilsley, J R Storry, M L Olsson","doi":"10.21307/immunohematology-2022-055","DOIUrl":"https://doi.org/10.21307/immunohematology-2022-055","url":null,"abstract":"<p><p>The MAM blood group system (International Society of Blood Transfusion [ISBT] 041) consists of one high-prevalence antigen to date, first detected in a 31-year-old woman during her third pregnancy. Epithelial membrane protein 3 (<i>EMP3</i>) was recently identified as the gene coding the MAM antigen. Six unique genetic variants have been described in <i>EMP3</i> in 11 MAM- individuals. EMP3 is an 18-kDa glycoprotein with a large extracellular domain containing at least one <i>N</i>-glycosylation site. The normal function of EMP3 is still unclear, but <i>ex vivo</i> culture of erythropoietic progenitor cells from MAM- individuals shows an increased yield of reticulocytes, suggesting that EMP3 acts as a brake during normal erythropoiesis. EMP3 is abundant on different cell types, including many epithelial tissues and blood cells. Interestingly, EMP3 expression has been suggested as a prognostic marker for a number of cancer types, both for good and poor prognoses. EMP3 may act as a tumor suppressor or an oncogene in different cancer contexts. The protein appears to interact with other cell surface receptors and affects the downstream signaling and function of these proteins. MAM- red blood cells express low levels of CD44 and, consequently, the antigens of the Indian blood group system are only weakly expressed. Clinically, the MAM blood group antigen is important with regard to blood transfusion and pregnancy. Anti-MAM can cause severe hemolytic disease of the fetus and newborn in some pregnancies but have little to no effect in other pregnancies. Cases are typically not detected until problems occur during pregnancy, making the availability of compatible blood a challenge.</p>","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"38 4","pages":"130-136"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10744114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rare case of clinically significant anti-c in a 1-year-old pediatric patient.","authors":"Sheetal Malhotra, Ashish Jain, Ratti Ram Sharma, Srinivasan Peyam","doi":"10.21307/immunohematology-2022-057","DOIUrl":"https://doi.org/10.21307/immunohematology-2022-057","url":null,"abstract":"","PeriodicalId":13357,"journal":{"name":"Immunohematology","volume":"38 4","pages":"137-138"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9944205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}